Entity family

Browse diseases

Named diseases, disorders, syndromes, injuries, and health conditions. Examples include epilepsy, diabetes, stroke.

23,712articles mentioning diseases

125,551disease mentions

18,081distinct diseases extracted

0%of mentions human-reviewed

Filter articles

JournalContent resourceEvidence policyAutomated confidence floorArticles per pageReset filters

“Reviewed + threshold” includes every confirmed correction plus unreviewed proposals at or above the selected model score.

All extracted diseases

Showing 61–120 of 18,081, ordered by supporting articles. Choose a disease to see its evidence.

Gastric Cancer96 T2D95 Acute Coronary Syndrome93 Autism90 Cervical Cancer89 Interstitial Lung Disease89 Frailty86 Ischaemic Heart Disease86 AIS83 Glaucoma82 Syphilis82 Osteoporosis82 Pulmonary Hypertension80 Interstitial Lung Disease (ILD)79 ILD78 MASLD77 SARS-CoV-277 Intracranial Aneurysms76 CArdiovascular diseases76 Liver Disease74 Pancreatic Cancer74 Pneumonia74 Obstructive Sleep Apnoea73 PD70 Post-traumatic stress disorder70 Pregnancy69 Cystic Fibrosis68 Autism Spectrum Disorder68 Anaemia67 Osteoarthritis66 UC66 Ischaemic stroke66 AD65 OSA65 Ovarian Cancer65 ADHD62 Malaria62 AF62 CSDH61 Coronary heart disease59 Non-communicable Diseases59 Ischemic Stroke58 HFpEF57 CHD57 Coeliac Disease57 Hypertrophic Cardiomyopathy57 Chronic Pain56 Traumatic Brain Injury56 Irritable Bowel Syndrome56 PWH55 SSc-ILD55 Sarcoidosis55 Psoriatic Arthritis54 Glioblastoma53 Chronic Liver Disease53 Pre-eclampsia51 Migraine51 Neisseria gonorrhoeae51 Bronchiectasis50 STEMI50

View all 18,081 diseases on one page

Articles mentioning diseases

23,712 articles · page 209 of 1976

PO:12:314 Nailfold capillaroscopic abnormalities in systemic lupus erythematosus: comparison with healthy controls and clinical–immunological correlations – preliminary data

lupusscimed · abstract · 2026-03-01 · 10 matching annotations

92.3%

systemic lupus erythematosus SLE scleroderma-like

…es This study aims to evaluate capillaroscopic abnormalities in systemic lupus erythematosus (SLE) patients versus healthy controls and to explore correlati…

PO:13:334 Grip strength, dexterity, and activities of daily living are independent predictors of poor quality of life in people living with systemic lupus erythematosus

lupusscimed · abstract · 2026-03-01 · 10 matching annotations

97.8%

Systemic Lupus Erythematosus SLE LupusQoL medications Purdue

…Objectives Patients with Systemic Lupus Erythematosus (SLE) often experience impaired health-related quality of life …

PT1:01 IFN-alpha-stimulated monocyte secretion of B cell activating factor (BAFF) is mediated through autophagy and extracellular vesicles in systemic lupus erythematosus (SLE)

lupusscimed · abstract · 2026-03-01 · 10 matching annotations

99.6%

SLE Bafilomycin A1 3-MA GW4869 brefeldin A

…sicular body formation by GW4869 also decreased BAFF secretion. SLE monocytes produced approximately double the levels of BAFF comp…

PT1:02 Mitochondrial expansion and interferon-driven bioenergetic reprogramming define CD4+ T cell dysfunction in systemic lupus erythematosus

lupusscimed · abstract · 2026-03-01 · 10 matching annotations

99.5%

SLE IFN-alpha IFN-I

…FN-driven metabolic reprogramming of CD4+ T cells contribute to SLE pathogenesis and highlight bioenergetic checkpoints as rational…

PT1:04 Differential expression of activation markers on dsDNA-reactive B-cells between healthy subjects and SLE patients reveals unconventional extrafollicular activation in SLE

lupusscimed · abstract · 2026-03-01 · 10 matching annotations

95.0%

systemic lupus erythematosus lupus nephritis SLE anti-CD19 CAR-T therapy

…Objectives Anti-dsDNA IgG antibodies are characteristic for systemic lupus erythematosus (SLE). Evidence suggests that these antibodies contribute to va…

PT4:06 Four-year safety and efficacy of deucravacitinib in systemic lupus erythematosus: results from the phase 2 PAISLEY SLE trial

lupusscimed · abstract · 2026-03-01 · 10 matching annotations

99.7%

SLE Deucravacitinib

…ent safety profile and sustained efficacy of deucravacitinib in SLE with up to 4+ years of treatment, with no new safety signals de…

PT5:06 Phenotypic and functional dysregulation of regulatory T cells in systemic lupus erythematosus

lupusscimed · abstract · 2026-03-01 · 10 matching annotations

98.8%

Systemic lupus erythematosus SLE

…Objectives Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by multi-or…

S3:05 Diagnostic performance of cerebrospinal fluid antibodies in inflammatory neuropsychiatric lupus with central nervous system involvement

lupusscimed · abstract · 2026-03-01 · 10 matching annotations

84.5%

NPSLE SN-SLE NP-non-AI

…nostic metrics.Results Among 85 patients, 25 were classified as NPSLE, 39 as SN-SLE and 21 as NP-non-AI. NPSLE patients were younger,…

S7:05 Ability of SLE-DAS and SLEDAI-2K to predict organ damage accrual in SLE: a real-world 7-year cohort study from Sweden

lupusscimed · abstract · 2026-03-01 · 10 matching annotations

93.7%

Systemic lupus erythematosus SLE-DAS SLE prednisone-equivalent KLURING

…Objectives Systemic lupus erythematosus (SLE) disease activity leads to irreversible organ damage, if n…

Community-based prediction models of cardiovascular events, acute exacerbations and all-cause mortality in individuals with chronic obstructive pulmonary disease: a systematic review and meta-analysis on behalf of the International Cardiovascular and Respiratory Alliance

bmjresp · abstract · 2026-02-27 · 10 matching annotations

95.3%

chronic obstructive pulmonary disease COPD AECOPD

…Introduction Preventable morbidity and mortality from chronic obstructive pulmonary disease (COPD) accrue from major adverse cardiovascular events (MACEs) …

Development of a novel meta-polygenic risk score for risk assessment and clinical manifestation prediction in systemic lupus erythematosus

rmdopen · abstract · 2026-02-25 · 10 matching annotations

96.8%

Systemic lupus erythematosus SLE Graves’ disease

…Background Systemic lupus erythematosus (SLE) is a clinically heterogeneous autoimmune disease with mul…

Long-term osteoprotective effects of IL-17A blockade with secukinumab in psoriatic arthritis: data from the PSARTROS-II study

rmdopen · abstract · 2026-02-25 · 10 matching annotations

93.8%

Psoriatic Arthritis PsA PsAMRIS secukinumab Disease Activity Score 28 Health Assessment Questionnaire interleukin (IL)-17A

…Area and Severity Index (p=0.001), C reactive protein (p=0.09), Psoriatic Arthritis Impact of Disease (p<0.001) and pain (p<0.001). Functional stat…